NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
NovaBridge Biosciences NBP
9 fiscal years on record · CNY · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
¥-0.21
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-21.4%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 9-year series below
Revenue
Net income
Per share
CNY -0.21
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-21.4%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-19.6%
Each CNY of equity lost 21 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−58.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−92.6%
−58.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.27B
Shares outstanding, FY2025
Change, 5 years+60.9%
Change, 10 years—
The share count grew 61% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
CNY 260.5M
total assets, end of FY2025
Total assetsCNY 260.5M
EquityCNY 230.9M
CashCNY 210.6M
Current ratio8.09×
Equity funds 89% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · CNY
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue ¥B
·
·
0.0
−0.0
0.1
1.5
0.0
0.1
0.0
Operating income ¥B
−0.1
−0.1
−0.1
−0.1
−2.3
0.5
−1.5
−0.4
−0.3
EBITDA ¥B
−0.1
−0.1
−0.1
−0.1
−2.3
0.5
−1.4
−0.4
−0.3
Income tax ¥B
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
·
Net income ¥B
−0.0
−0.0
−0.2
−0.4
−2.3
0.5
−1.5
−0.4
−0.3
EPS, diluted ¥
−0.21
−0.27
−17.62
−30.38
−4.82
6.90
−462.74
−141.91
−51.93
Dividend / sh ¥
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−21.4
−10.0
−62.9
−65.5
−73.5
26.2
·
·
·
Shares out B
0.27
0.19
0.19
0.19
0.18
0.16
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed